

Change in the nomination committee's proposal regarding election of board members of Bio-Works

The Nomination Committee's proposal for the election of board members was reported in the notice for Bio-Works' Annual General Meeting, which was announced via a press release on April 23, 2024. Johan Sedihn has since informed that he has declined re-election at the Annual General Meeting. The Nomination Committee has now informed the company that it has decided to supplement the proposal with the nomination of an additional member, Thomas Gür.

Thomas Gür was born in 1959 and has over 40 years of experience in the areas of communication, investor relations, media handling, and public relations. He has served as an advisor on international issues and as a board member of both listed and unlisted companies. He has been the Chairman of the Board of Tellusgruppen AB since 2020. He is the owner and founder of Ölander & Gür AB, and Klasse AB. He was the external CEO of Accelerator Nordic AB in 2013-2014. He has also served as a political commentator on the editorial pages for SvD, Göteborgs Posten, Finanstidningen, and ÖstgötaCorren. He is a former UN officer and press secretary for the Chief of Defence.

Thomas Gür holds a Bachelor of Arts degree in Economic History and Economics from Lund University.

The Nomination Committee's proposal for the election of board members therefore includes the re-election of Peter von Ehrenheim, Kirsti Gjellan, and Peter Nählstedt, as well as the new election of Jonas Ahlen and Thomas Gür, with Peter von Ehrenheim as Chairman of the Board.

For more information, please contact:

Peter von Ehrenheim
070-6675711

About Bio-Works

Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works' next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North ("BIOWKS"), and FNCA Sweden AB is appointed Certified Adviser. For more information, visit www.bio-works.com.

Attachments

[Change in the nomination committee's proposal regarding election of board members of Bio-Works](#)